TSHA Live signals | Maximize Profits with Getagraph.com

SELL 157557 min ago

@ $1.475

Issued: 14 Feb 2024 @ 15:29

Return: 132.54%

Previous signal: Feb 14 - 13:58

Previous signal: Buy

Return: 2.43 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	2.48M
Average Volume	2.38M
Market Cap	641.47M
EPS	$0 ( 2024-05-14 )
Next earnings date	( $-0.100 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.40
ATR14	$0.00900 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-29	Stalfort John A Iii	Buy	49 220	Common Stock
2024-05-29	Stalfort John A Iii	Buy	98 440	Stock Option (right to buy)
2024-05-29	Long Alison S	Buy	98 440	Stock Option (right to buy)
2024-05-29	Long Alison S	Buy	49 220	Common Stock
2024-05-29	Donenberg Phillip B.	Buy	49 220	Common Stock

INSIDER POWER
95.58
Last 98 transactions
Buy: 30 046 285 \| Sell: 943 112

Volume Correlation

Long: 0.16 (neutral)

Short: -0.84 (strong negative)

Signal:(44.935) Neutral

Taysha Gene Therapies, Correlation

10 Most Positive Correlations
MACK	0.884
MEDP	0.882
TRVI	0.874
PLMR	0.873
FPXI	0.872
FCYIX	0.862
PHO	0.859
TRMB	0.857
HTHT	0.853
CGO	0.853

10 Most Negative Correlations
SSRM	-0.872
CYAN	-0.871
LTRX	-0.865
WISA	-0.857
MFIN	-0.85
WTER	-0.846
VLCN	-0.845
SSP	-0.832
ROIC	-0.83
RAPT	-0.829

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Taysha Gene Therapies, Correlation - Currency/Commodity

0.59
( weak )

0.56
( weak )

0.00
( neutral )

-0.23
( neutral )

-0.60
( weak negative )

Taysha Gene Therapies, Financials

Annual	2023
Revenue:	$15.45M
Gross Profit:	$14.08M (91.13 %)
EPS:	$-0.960

FY	2023
Revenue:	$15.45M
Gross Profit:	$14.08M (91.13 %)
EPS:	$-0.960

FY	2022
Revenue:	$2.50M
Gross Profit:	$15 000.00 (0.60 %)
EPS:	$-3.86

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-4.64

Financial Reports:

No articles found.

Taysha Gene Therapies, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Taysha Gene Therapies,

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.